Elicio Therapeutics Inc (ELTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$2.41-3.60%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ELTX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue evaluation of Phase 2 AMPLIFY-7P trial data, including subgroup analyses, and refine Phase 3 development strategy for ELI-002 7P in adjuvant pancreatic cancer.
Stated as a priority in 4 of last 4 quarters. The Phase 2 AMPLIFY-7P trial did not meet its primary DFS endpoint in the intent-to-treat population but post-hoc analyses showed a DFS hazard ratio of 0.65 (p=0.048) in the R0 resected subgroup and ~14% absolute DFS improvement during active treatment. Management continues to refine the Phase 3 strategy focusing on patients with lower residual disease burden. The trajectory shows persistent focus with emerging subgroup efficacy signals supporting the refined development path.
“Phase 2 AMPLIFY-7P trial did not meet its primary endpoint but continues to evaluate pre-specified subgroups and refine Phase 3 strategy.”
“Focused on advancing Phase 2 AMPLIFY-7P trial and anticipate event-driven primary DFS analysis mid-year 2026.”
“Anticipated AMPLIFY-7P Phase 2 event-driven DFS analysis expected in 1H 2026.”
“AMPLIFY-7P Phase 2 trial ongoing with expected DFS endpoint analysis timing updated to first half of 2026.”
Maintain sufficient liquidity to support operations through Q1 2027, including recent financing and cash management.
Stated as a priority in 4 of last 4 quarters. Cash and cash equivalents increased from $14.9 million in 2026-Q1 to $23.5 million in 2026-Q2, supported by $15 million raised in July 2026. Management projects cash runway into Q1 2027, extending prior guidance of Q4 2026. The trajectory shows delivering on liquidity extension through financing and cash management.
“Recent $15 million financing strengthens balance sheet to support cash runway into Q1 2027.”
“Cash runway expected to extend into Q4 2026, beyond anticipated DFS readout.”
“Cash and equivalents and ATM proceeds expected to support operations into Q3 2026.”
“Cash and equivalents expected to support operations into Q1 2026.”
Focus Phase 3 trial design on R0 resected patients with extended dosing to enhance durability and clinical benefit.
Stated as a priority in 2 of last 4 quarters. Following Phase 2 AMPLIFY-7P results, management refined Phase 3 strategy to focus on R0 resected patients with extended dosing to improve durability. The company plans regulatory engagement to align on trial design. The trajectory shows active development planning based on clinical insights.
“Refined Phase 3 development strategy focused on R0 resected patients with additional dosing.”
“Plan to request End-of-Phase 2 meeting with FDA to align on Phase 3 trial design for ELI-002 7P.”
Pursue financing and partnerships to support Phase 3 development and broader pipeline advancement.
Stated as a priority in 2 of last 4 quarters. Management raised approximately $13 million via ATM program in first half 2026 and $15 million in July 2026, and continues to evaluate strategic financing and partnerships to support Phase 3 and pipeline. The trajectory shows ongoing capital raising and partnership evaluation.
“Evaluating multiple strategic financing and partnering opportunities to support future clinical development.”
“Company raised net proceeds through ATM program to support operations and development.”
Start Phase 1 trial combining ELI-002 7P with RAS small molecule inhibitor and anti-PD-1 inhibitor in metastatic pancreatic cancer in Q4 2026.
Newly stated in 2026-Q2. Management announced plans to start a Phase 1 combination trial in metastatic pancreatic cancer in Q4 2026. This is a new strategic clinical development priority with no prior quarterly mentions. The trajectory is newly established.
“Plan to initiate Phase 1 combination study of ELI-002 7P with RAS small molecule inhibitor with or without anti-PD-1 inhibitor in metastatic pancreatic cancer in Q4 2026.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Over the trailing year it converted 1.00x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
9 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 46% of the time over the next year (vs 53% for the rest of the cohort, n=3872).
Not investment advice. As of 2026-09-04.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.